He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Subscribe To Our Newsletter & Stay Updated
